# A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors

Source: https://onco.cc/trials/nct06703177/  
OnCo record `nct06703177` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of SHR-8068, Bevacizumab, Leucovorin (folinic acid), Adebrelimab and Capecitabine in advanced solid tumours, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.

## Summary

A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors is a phase 1/2 interventional study registered as NCT06703177 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 876 participants planned, started 2025-02-18 and due to reach its primary completion in 2026-01-01. Interventions recorded: SHR-1826, SHR-4642, SHR-9839, SHR-8068, Bevacizumab Injection and Fluorouracil Injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06703177
- Phase: 1/2
- Setting: Phase IB/II Study of Safety, Tolerability and Efficacy of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors
- Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Enrolled: 876

## Sources

- ClinicalTrials.gov NCT06703177: https://clinicaltrials.gov/study/NCT06703177

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Adebrelimab](https://onco.cc/drugs/adebrelimab/), [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Capecitabine](https://onco.cc/drugs/capecitabine/), [Leucovorin (folinic acid)](https://onco.cc/drugs/leucovorin/), [SHR-8068](https://onco.cc/drugs/shr-8068/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct06703177.json